ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Loxo Oncology
234.66
0.0000
成交量：
- -
成交額：
- -
市值：
72.17億
市盈率：
-112.40
高：
234.66
開：
234.66
低：
234.66
收：
234.66
52周最高：
234.93
52周最低：
103.50
股本：
3,075.46萬
流通股本：
2,752.00萬
量比：
- -
換手率：
- -
股息：
- -
股息率：
- -
每股收益(TTM):
-2.0877
每股收益(LYR):
-5.3102
淨資產收益率：
--
總資產收益率：
--
市淨率：
19.03
市盈率(LYR):
-44.19
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字：
Loxo Oncology
交易所：
NASDAQ
成立時間：
- -
員工人數：
- -
公司地址：
- -
官網：
http://www.loxooncology.com
郵編：
- -
電話：
- -
傳真：
- -
簡介：
Loxo Oncology, Inc.於2013年5月9號在特拉華州成立。公司開發有針對性的基因定義的患者群體的治療癌症的小分子療法。公司的開發方式轉換了相關癌症轉換成藥物，這些藥物能夠有效的和高選擇性的達到關鍵科學見解的預期目標。這些藥物通常能夠達到更高的目標任務和改善相關腫瘤的反應。 公司識別和優先考慮的目標有兩種方式。首先，該公司使用的臨床試驗數據來評估藥物的發展，響應信號和識別那些承諾也證明藥物的具體限制，如吸收差，差的分佈或有害的副作用。第二，該公司評估學術研究發現新的目標與新興的驗證。一旦確定目標,公司使用先進的第三方技術來開發候選產品旨在增強目標接觸和特異性。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LOXO/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"LOXO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","market":"US","secType":"STK","nameCN":"Loxo Oncology","latestPrice":234.66,"timestamp":1557432000000,"preClose":234.66,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":27520039,"shares":30754634,"eps":-2.087713,"marketStatus":"停牌","change":0,"latestTime":"03-23 13:16:03 EDT","open":234.66,"high":234.66,"low":234.66,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.087713,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1406865600000,"exchange":"NASDAQ","adjPreClose":234.66,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","floatShares":27520039,"roa":"--","roe":"--","lyrEps":-5.31023,"shares":30754634,"dividePrice":0,"high":234.66,"amplitude":0,"preClose":234.66,"low":234.66,"week52Low":103.5,"pbRate":"19.03","week52High":234.93,"institutionHeld":0,"latestPrice":234.66,"eps":-2.087713,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.087713,"open":234.66,"prevYearClose":234.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LOXO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-11-08","symbol":"LOXO","fiscalQuarterEnding":"2018/09","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-2.26},{"market":"US","date":"2018-08-09","symbol":"LOXO","fiscalQuarterEnding":"2018/06","expectedEps":-0.54,"name":null,"time":"盤前","type":"earning","dateTimestamp":1533787200000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2018-05-08","symbol":"LOXO","fiscalQuarterEnding":"2018/03","expectedEps":-0.6,"name":null,"time":"盤前","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2018-03-01","symbol":"LOXO","fiscalQuarterEnding":"2017/12","expectedEps":-1.22,"name":null,"time":"盤前","type":"earning","dateTimestamp":1519880400000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2017-11-02","symbol":"LOXO","fiscalQuarterEnding":"2017/09","expectedEps":-1.38,"name":null,"time":"盤前","type":"earning","dateTimestamp":1509595200000,"reportTimeType":"pre","actualEps":-1.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LOXO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.loxooncology.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Loxo Oncology, Inc.於2013年5月9號在特拉華州成立。公司開發有針對性的基因定義的患者群體的治療癌症的小分子療法。公司的開發方式轉換了相關癌症轉換成藥物，這些藥物能夠有效的和高選擇性的達到關鍵科學見解的預期目標。這些藥物通常能夠達到更高的目標任務和改善相關腫瘤的反應。 公司識別和優先考慮的目標有兩種方式。首先，該公司使用的臨床試驗數據來評估藥物的發展，響應信號和識別那些承諾也證明藥物的具體限制，如吸收差，差的分佈或有害的副作用。第二，該公司評估學術研究發現新的目標與新興的驗證。一旦確定目標,公司使用先進的第三方技術來開發候選產品旨在增強目標接觸和特異性。","exchange":"NASDAQ","name":"Loxo Oncology","nameEN":"Loxo Oncology"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":null}}